Cite
HARVARD Citation
Makker, V. et al. (2016). A multicenter, single‐arm, open‐label, phase 2 study of apitolisib (GDC‐0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). Cancer. 122 (22), pp. 3519-3528. [Online].